UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000005060 |
|---|---|
| Receipt number | R000006009 |
| Scientific Title | A randomized phase II study of XELOX plus Bevacizumab versus XELIRI plus Bevacizumab for advanced colorectal cancer with or without mitochondrial transcription factor A (mtTFA) expression. |
| Date of disclosure of the study information | 2011/02/14 |
| Last modified on | 2023/09/01 16:52:43 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2011/02/09 17:54:26 | ||
| 2 | Update | 2023/09/01 16:50:43 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code TEL Last name of contact person Last name of contact person Zip code TEL Name of primary person or sponsor Institute Organization Post marketing survey by drug manufacture etc., specified by Japanese law. Email3 Organization Organization Address Address Tel |
|
| 3 | Update | 2023/09/01 16:52:43 | Recruitment status Date of IRB |
